Citigroup’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $45.8M | Buy |
+300,000
| New | +$46M | 0.02% | 679 |
|
|
2023
Q3 | – | Sell |
-10,300
| Closed | -$1.04M | – | 5752 |
|
|
2023
Q2 | $1.04M | Buy |
+10,300
| New | +$1.03M | ﹤0.01% | 2821 |
|
|
2021
Q1 | – | Sell |
-110,200
| Closed | -$10.4M | – | 7045 |
|
|
2020
Q4 | $10.4M | Sell |
110,200
-20,000
| -15% | -$1.75M | 0.01% | 1520 |
|
|
2020
Q3 | $11.3M | Buy |
130,200
+36,300
| +39% | +$3.14M | 0.01% | 1276 |
|
|
2020
Q2 | $8.2M | Sell |
93,900
-38,200
| -29% | -$3.3M | 0.01% | 1457 |
|
|
2020
Q1 | $10.9M | Sell |
132,100
-29,200
| -18% | -$2.61M | 0.01% | 1108 |
|
|
2019
Q4 | $15.3M | Sell |
161,300
-3,600
| -2% | -$323K | 0.01% | 1147 |
|
|
2019
Q3 | $14.3M | Buy |
164,900
+11,600
| +8% | +$1.04M | 0.01% | 1144 |
|
|
2019
Q2 | $14M | Buy |
153,300
+100,402
| +190% | +$8.5M | 0.01% | 1164 |
|
|
2019
Q1 | $4.56M | Sell |
52,898
-14,955
| -22% | -$1.2M | ﹤0.01% | 1873 |
|
|
2018
Q4 | $5.22M | Buy |
67,853
+25,222
| +59% | +$1.96M | 0.01% | 1780 |
|
|
2018
Q3 | $3.29M | Sell |
42,631
-1,563
| -4% | -$116K | ﹤0.01% | 2257 |
|
|
2018
Q2 | $2.99M | Buy |
44,194
+15,401
| +53% | +$1.06M | ﹤0.01% | 2321 |
|
|
2018
Q1 | $2.09M | Sell |
28,793
-46,202
| -62% | -$3.52M | ﹤0.01% | 2558 |
|
|
2017
Q4 | $5.64M | Buy |
74,995
+31,917
| +74% | +$2.41M | ﹤0.01% | 1714 |
|
|
2017
Q3 | $3.31M | Buy |
43,078
+26,338
| +157% | +$1.99M | ﹤0.01% | 2132 |
|
|
2017
Q2 | $1.25M | Sell |
16,740
-148,651
| -90% | -$10.5M | ﹤0.01% | 3083 |
|
|
2017
Q1 | $11M | Buy |
165,391
+25,668
| +18% | +$1.71M | 0.01% | 1071 |
|
|
2016
Q4 | $9.12M | Buy |
139,723
+115,841
| +485% | +$7.51M | 0.01% | 1263 |
|
|
2016
Q3 | $1.69M | Sell |
23,882
-447
| -2% | -$32.6K | ﹤0.01% | 2673 |
|
|
2016
Q2 | $1.8M | Buy |
24,329
+6,250
| +35% | +$432K | ﹤0.01% | 2421 |
|
|
2016
Q1 | $1.17M | Buy |
18,079
+11,160
| +161% | +$759K | ﹤0.01% | 3139 |
|
|
2015
Q4 | $533K | Sell |
6,919
-16,740
| -71% | -$1.33M | ﹤0.01% | 3789 |
|
|
2015
Q3 | $1.95M | Buy |
23,659
+18,749
| +382% | +$1.67M | ﹤0.01% | 2465 |
|
|
2015
Q2 | $433K | Buy |
+4,910
| New | +$450K | ﹤0.01% | 3834 |
|
|
2014
Q1 | – | Sell |
-3,460
| Closed | -$249K | – | 7145 |
|
|
2013
Q4 | $249K | Hold |
3,460
| – | – | ﹤0.01% | 4470 |
|
|
2013
Q3 | $238K | Sell |
3,460
-5,580
| -62% | -$369K | ﹤0.01% | 4015 |
|
|
2013
Q2 | $573K | Buy |
+9,040
| New | +$588K | ﹤0.01% | 3366 |
|
Other funds holding NVS
Citigroup's NVS Position: Q1 2026 in Review
Citigroup increased its Novartis (NVS) stake by 389% in Q1 2026, buying an estimated $42.5M and bringing the position to 348,789 shares worth $53.3M. The position accounts for 0.02% of the portfolio, ranked #624.
Citigroup first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $88.6M in Q1 2024. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Citigroup held 348,789 shares of Novartis worth $53.3M as of Q1 2026.
- Citigroup bought 277,455 Novartis shares in Q1 2026, an estimated $42.5M.
- Novartis made up 0.02% of Citigroup's portfolio in Q1 2026, its #624 holding.
- Citigroup first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Novartis position peaked at $88.6M in Q1 2024.
- 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.